Construction has reportedly begun on the first phase of the Line, Saudi Arabia's insanely ambitious plan to build a 170-km (105 mile)-long gleaming megacity in the desert. We also now know how many ...

Ibrutinib shows similar real-world overall survival outcomes for high-risk and non-high-risk CLL/SLL patients, suggesting cytogenetic risk factors do not affect its efficacy. The study utilized a ...

Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences’ Trodelvy ...

In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line treatment, with a 77% objective response rate and 96% disease control rate.

Levetiracetam reduces tonic-clonic seizures by over 77% in clinical studies. Ethosuximide is highly effective for absence seizures, especially in children. Valproate remains the gold standard for ...

The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...

The Starting Line may be getting older, but they’re still young at heart. To prove it, they’re releasing their first album in 18 years, aptly-titled Eternal Youth this fall. Today, they release new ...